{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:10Z","timestamp":1793806150505,"version":"4.6.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Schizophrenia is a severe chronic mental disorder, and olanzapine is widely used in its treatment. However, the expanding and heterogeneous literature on olanzapine in schizophrenia has not been comprehensively characterized from a bibliometric perspective. Therefore, this study aimed to systematically characterize the research landscape, hotspots, emerging frontiers, and knowledge evolution of olanzapine in the treatment of schizophrenia from 2010 to 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Literature on olanzapine for the treatment of schizophrenia published between January 1, 2010, and March 29, 2026, was retrieved from the Web of Science Core Collection. CiteSpace (version 6.4.R2) and the Bibliometrix R package were used for bibliometric and visual analyses. Multiple bibliometric characteristics were analyzed, including publication trends, national and institutional distributions, core authors, journal distributions, co-citation of references, co-occurrence, clustering, keyword burst detection, and disciplinary biclustering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 3943 valid publications were included. Annual publication volume generally increased over the study period, despite periodic minor fluctuations. The United States, China, and the United Kingdom accounted for the largest shares of publication output. From a bibliometric perspective, University College London stood out as a hub node within the collaboration network. Correll CU and Leucht S represented highly productive contributors.\n                      <jats:italic toggle=\"yes\">Schizophrenia Research<\/jats:italic>\n                      was the most productive journal in terms of publication output. Keyword analysis indicated that the research focus gradually shifted from evaluation of drug efficacy and dosage-form development to metabolic risk management, personalized treatment, and real-world clinical research. Recent research primarily focused on population-based cohort studies, comparative evaluations of treatment efficacy, clinical practice guidelines, and treatment-related risk assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Research on olanzapine for the treatment of schizophrenia is ongoing. Current studies have shifted from efficacy verification to safety monitoring, with growing emphasis on population-based individualized dose adjustment, metabolic risk management, and large-sample comparative clinical studies for clinical guideline optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050747","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:02:07Z","timestamp":1790359327000},"page":"e50747","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Research trends in olanzapine in treating schizophrenia from 2010 to 2026"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1583-7183","authenticated-orcid":false,"given":"Na","family":"Shu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Luzhou Mental Hospital, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9216-9223","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, Luzhou Mental Hospital, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0064-3610","authenticated-orcid":false,"given":"Ling Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Luzhou Mental Hospital, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6954-9302","authenticated-orcid":false,"given":"Yan","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Luzhou Mental Hospital, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2993-7176","authenticated-orcid":false,"given":"Min","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, Luzhou Mental Hospital, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1925-8773","authenticated-orcid":false,"given":"Hai Ming","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Luzhou Mental Hospital, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia.","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"1702808","DOI":"10.3389\/fpsyt.2026.1702808","article-title":"Global, regional, and national burden of schizophrenia: epidemiological trends, decomposition, joinpoint analysis, and projections to 2036 based on GBD 2021.","volume":"17","author":"Zhou","year":"2026","journal-title":"Front Psychiatry"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R4-20261104","first-page":"CD001359","article-title":"Olanzapine for schizophrenia.","author":"Duggan","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.12740\/PP\/214532","article-title":"Olanzapine in the treatment of schizophrenia in adolescents - mechanisms of action and therapeutic efficacy.","volume":"59","author":"Nowak","year":"2025","journal-title":"Psychiatr Pol"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.3390\/jcm14228125","article-title":"Drawbacks of olanzapine therapy: an emphasis on its metabolic effects and discontinuation.","volume":"14","author":"Oruch","year":"2025","journal-title":"J Clin Med"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/NDT.S345046","article-title":"Early lipid metabolic effects of the anti-psychotic drug olanzapine on weight gain and the associated gene expression.","volume":"18","author":"Chen","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1570159X23666240918103730","article-title":"Olanzapine-induced weight gain and glycolipid metabolism aberrations in first-episode and antipsychotic-na\u00efve schizophrenia patients: a longitudinal study.","volume":"23","author":"Li","year":"2025","journal-title":"Curr Neuropharmacol"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/ijnp\/pyad029","article-title":"Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis.","volume":"26","author":"Correll","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"412","DOI":"10.62641\/aep.v52i4.1681","article-title":"Evaluation of clinical correlation between insulin resistance and antipsychotic drug therapy in patients with schizophrenia.","volume":"52","author":"Wang","year":"2024","journal-title":"Actas Esp Psiquiatr"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2165\/00003495-200565080-00006","article-title":"First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.","volume":"65","author":"Kelly","year":"2005","journal-title":"Drugs"},{"key":"R13-20261104","first-page":"CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia.","volume":"2010","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.","volume":"165","author":"Wu","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"19m12769","DOI":"10.4088\/JCP.19m12769","article-title":"Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study.","volume":"81","author":"Potkin","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s40265-021-01568-0","article-title":"Olanzapine\/samidorphan: first approval.","volume":"81","author":"Paik","year":"2021","journal-title":"Drugs"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2147\/NDT.S209284","article-title":"A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future.","volume":"15","author":"Citrome","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"2045125318820207","DOI":"10.1177\/2045125318820207","article-title":"Trends in the scientific literature on atypical antipsychotic drugs in the United Kingdom: a bibliometric study.","volume":"9","author":"L\u00f3pez-Mu\u00f1oz","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4306\/pi.2013.10.1.8","article-title":"Trends in scientific literature on atypical antipsychotics in South Korea: a bibliometric study.","volume":"10","author":"L\u00f3pez-Mu\u00f1oz","year":"2013","journal-title":"Psychiatry Investig"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.11622\/smedj.2014006","article-title":"A bibliometric study of scientific research conducted on second-generation antipsychotic drugs in Singapore.","volume":"55","author":"L\u00f3pez-Mu\u00f1oz","year":"2014","journal-title":"Singapore Med J"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"102640","DOI":"10.1016\/j.cpcardiol.2024.102640","article-title":"Bibliometric analysis: a few suggestions.","volume":"49","author":"Hassan","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"34224","DOI":"10.52965\/001c.34224","article-title":"Combination olanzapine and samidorphan for the management of schizophrenia and bipolar 1 disorder in adults: a narrative review.","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol Res"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.0207e04","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.","volume":"68","author":"Lieberman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study.","volume":"177","author":"Correll","year":"2020","journal-title":"Am J Psychiatry"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines.","volume":"133","author":"Donthu","year":"2021","journal-title":"J Bus Res"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apnu.2024.12.005","article-title":"Efficacy and safety evaluation of olanzapine treatment for schizophrenia patients: a retrospective data analysis.","volume":"54","author":"Li","year":"2025","journal-title":"Arch Psychiatr Nurs"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/FTD.0000000000001227","article-title":"Therapeutic drug monitoring of olanzapine: effects of clinical factors on plasma concentrations in psychiatric patients.","volume":"46","author":"Ansermot","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2215-0366(23)00366-8","article-title":"Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data.","volume":"11","author":"Efthimiou","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.07-9492LSF","article-title":"Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses.","volume":"22","author":"Falagas","year":"2008","journal-title":"FASEB J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:02:48Z","timestamp":1793804568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050747"}},"subtitle":["A bibliometric analysis based on the Web of Science Core Collection"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":32,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050747","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}